Strategic partnerships Telix actively expands collaboration through partnerships with research centers and imaging groups, such as the Melbourne Theronastic Innovation Centre and United Imaging Group, presenting opportunities to co-develop radiopharmaceutical programs, access investigational sites, and expand regional clinical trial networks.

Global expansion Recent facility openings and expansion in Australia and Oceania indicate a growing regional manufacturing and treatment footprint, offering potential for localized supply agreements, faster distribution, and joint ventures to serve oncology and rare disease markets.

Phase 3 momentum Progress in high-visibility Phase 3 programs like ProstACT for advanced prostate cancer provides a platform for downstream opportunities in companion diagnostics, post-approval studies, and payer/real-world evidence collaborations to enhance market access.

Theranostics focus Telix’s radiopharmaceutical focus and theranostics collaborations position you to offer end-to-end solutions, including radioligand production partnerships, supply chain optimization, and imaging-guided treatment capabilities for oncology clinics.

Executive and tech readiness With a significant global headcount and a tech stack spanning CLM, sourcing, project management, and analytics, there is opportunity to engage in enterprise-level procurement, contract optimization, and digital collaboration programs to accelerate commercial activities and trials.